---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108898"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:20:17.923777+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology Q2 2025 net loss $18.4M, cash $90.4M; MICVO data milestones ahead

## Summary
- Revenue of $2.8M from milestone payment for suvemcitug approval in China, compared to $0 in Q2 2024.
- Net loss $18.4M ($0.30 per share) vs $17.3M ($0.29) in prior year; adjusted loss $15.3M.
- Cash, cash equivalents and short-term investments $90.4M; runway into H2 2026.
- Preliminary MICVO monotherapy data in 2L/3L HNSCC expected H2 2025; combination with pembrolizumab data also H2 2025.
- R&D expenses rose to $17.1M, driven by increased MICVO manufacturing and trial costs.

## SEC filing metadata
- accession: 0000950170-25-108898
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017025108898/0000950170-25-108898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017025108898/pyxs-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108898
- JSON: https://secwatch.observer/filing/0000950170-25-108898.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.